Product of the Week

LiposoFast-Basic
Vergrößern

Avestin

LiposoFast-Basic

1. Principle of Operation 

The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. The sample is passed through the membrane by pushing the sample back and forth between two syringes. 

2. Temperature Control 

The entire LiposoFast-Basic can be immersed in a water bath for use with high transition temperature lipids or heat sensitive compounds. 

3. Accessories 

The optional LiposoFast-Stabilizer was designed to simplify the repetitive use of the LiposoFast-Basic as well as the extrusion of highly concentrated samples. It accommodates both 0.5mL and 1.0mL syringes. 

4. Free Trial 

This instrument is available for a free trial. Simply contact us and we can send it to you. If after the trial you are not satisfied with it or it does not suit your research, simply send it back.


Contact:

Avestin Europe GmbH

Weinheimer Straße 64b

68309 Mannheim 

Deutschland

Michael Fischer

Tel. +49 (0621) 724-5980

Fax +49 (0621) 724-5813

avestin@avestin.net

www.avestin.com 

none

Products

Acro Associates, Inc.

The Model 936 pneumatic pinch valve is a 2-way, compressed air or gas operated pinch valve that is designed to work with Shore A class flexible tubing.

Acro Associates, Inc.
  • Designed for bioprocessing systems applications such as single-use disposable (SSD), filling, mixing, dispensing, me- dia production and more
  • Supports user selectable tubing up to 1.5” Outer Diameter and 4 bar/58 psi media pressure
  • Built in user safety for finger crushing hazards for GLP/GMP
  • Available in 316L stainless steel or black anodized alumi- num material formats


The Model 936 pneumatic pinch valve is a 2-way, compressed air or gas operated pinch valve that is designed to work with Shore A class flexible tubing. Its robust design allows users the flexibility to select various types of biopharm or medical tubing within guideline specifications. The panel mount ready unit support tubing sizes from 1.0 to 1.5 inch outer diameter (25—38 mm), up to 65-Shore A and media pressures up to 58 psi/4 bar that allow for medium to large fluid volume movement. Built in tube loading and replace- ment safety lockouts ensures GLP/GMP compliancy preventing us- er finger or hand injury. Internal seals prevent liquid penetration inside the unit. Configured as either normally-open, or closed de- fault formats. Panel or base mountable and an optional state sen- sor is available.


Contact Information:

Acro Associates Europe

Windmolen 22

7609 NN Almelo

The Netherlands

Tel.: +31 (0) 548 659 084

Fax: +31 (0) 548 659 010

europe@acro.eu.com

www.acro.eu.com


Acro Associates North America

1990-A Olivera Road Concord, CA 94520 USA

Tel.: +1 925 676 8828

Fax: +1 925 680 8113

info@acroassociates.com

www.acroassociates.com

BioTek

Synergy™ Neo is an HTS multi-mode microplate reader designed specifically for today's screening and core laboratories.

BioTek

Synergy Neo has all the features expected in an HTS screening instrument, including multiple parallel detectors for ultra-fast measurements and a dedicated filter-based system for live cell assays. With a load/unload plate transfer time of about 6 seconds per plate, Synergy Neo ’s optional integrated plate stacker is the fastest stacker on the market, allowing walk-away automation of short- or long-term assays. Synergy Neo also meets today's diverse assay requirements by incorporating features such as a powerful 100 mW laser-based excitation source for Alpha assays, a unique patented Hybrid optical design, advanced temperature control to 65°C, orbital and linear shaking. Ease of use and user confidence are key to the design of Synergy Neo ’s unique filter cubes that are barcode labeled for positive filter ID - limiting the possibility of errors and streamlining the workflow, while an available image-based barcode reader can scan both 1D and 2D barcode-labeled plates. The outstanding functionality of Synergy Neo is controlled by the powerful, yet easy to use, Gen5 2.0 Data Analysis Software. If you are involved in the HTS screening world, Synergy Neo was designed just for you.


For more information please visit: www.biotek.com

Cambridge Epigenetix Ltd.

Cambridge Epigenetix Ltd., a spin out biosciences company, has announced the launch of its innovative TrueMethyl™ Kits.

Cambridge Epigenetix Ltd.

Available to order now via its website at www.cambridge-epigenetix.com, the kits represent a ground-breaking development for the epigenetics industry.  

TrueMethyl™ brings unprecedented clarity to the analysis of DNA by providing quantitative, accurate and repeatable single-base resolution sequencing of the modified bases hydroxymethylcytosine (5-hmC) and methylcytosine (5-mC) for the first time.  Early studies indicate that these modifications may have distinct and important physiological functions.

Traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. The high quality and easy to use TrueMethyl™ kits utilize innovative oxidative bisulfite sequencing (oxBS-Seq), a chemistry-based technology invented by Prof. Shankar Balasubramanian and Michael Booth from the University of Cambridge.

TrueMethyl™ kits can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Trials of the kits conducted at leading research centers around the world have already begun to yield new insights into genome function and highlighted the advantages of TrueMethyl™ relative to traditional approaches.

Prof. Wolf Reik, group leader at the The Babraham Institute and the senior author of the recently published Cell Stem Cell paper which is the first published study using TrueMethyl™ said, “Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. Consequently, this pioneering analytical method opens new avenues for basic research, pharmaceutical discovery and diagnostics. This technology was pivotal in enabling us to accurately profile 5-hmC and 5-mC during demethylation of DNA.”

To find out more about Cambridge Epigenetix and the TrueMethyl kits please visit www.cambridge-epigenetix.com or email info@cegx.co.uk.


Media Contact:

Holly Jobbins, The Scott Partnership


Tel: +44 (0) 1477 539539


E-mail: hmj@scottpr.com 

Corporate Contact:

Dr. Jason Mellad, CEGX


Tel: 1-800-754-5916


Email: jason@cegx.co.uk

Olympus

Olympus will exhibit its BX3 upright microscope systems and VS120 virtual slide scanner at ECP 2013.

Olympus

Designed specifically to meet the needs of a range of pathology applications, the systems ensure robust diagnosis and discovery alongside ergonomic operation.    

Enhancing the workflow of research and diagnostic centres alike, the latest range of Olympus pathology microscope systems and accessories will be on show at the 25th European Congress of Pathology (ECP) 2013, 31 August – 4 September in Lisbon, Portugal. Delegates can visit booth 14 to view the Olympus BX3 range of upright microscopes and the Olympus VS120 virtual slide scanner.  

The BX3 range of upright microscope offers complete flexibility in pathology applications due to a modular design. Ergonomics is a priority, and each user can set up the microscope to match their posture, for both comfort and convenience. The range includes several models focused on either clinical or research microscopy, and delegates of ECP will have a chance to view the fully automated BX63, the research-focused BX53 and the BX43 clinical imaging system.

The BX63 delivers high performance automated microscopy for research applications, and the system on display at booth 14 will also feature the unique dual chip Olympus DP80 digital camera. Combining colour and monochrome chips within the same housing allows joint colour and fluorescent imaging in pathology applications, for example when combining histological staining with fluorescent dyes on the same sample. The BX3 range lends itself to easy integration into existing workflows, and visitors can also discover how the BX43 clinical microscope is compatible with both third party cameras and software.

With a modular design, the research-focused BX53 can be easily customised and the system on display at ECP will feature the Olympus discussion tube unit. Allowing multiple users to observe the same specimen using separate eyepieces, this system is ideal for both teaching and consulting, as all users see the actual image, not a digital representation. The unit is a powerful tool for reviewing difficult cases with other pathologists and colleagues to discuss diagnoses, and delegates of ECP are invited to bring along their own samples to examine with colleagues.

Also on display will be the Olympus VS120 virtual slide scanner, which features the flexibility, resolution and image quality necessary for meeting the demands of pathology research workflows. The system creates a “virtual slide” high-resolution image of the complete specimen at a range of magnifications, which can be electronically stored on a central server. This enables instant access and simultaneous viewing anywhere in the world, omitting the need to transport specimens between laboratories, reducing slide archives and securing a permanent digital record of the sample.

Delegates will discover how the latest in Olympus imaging technology enables new possibilities for clinical and research pathology applications alike.

For more information on ECP 2013, visit www.esp-congress.org.

To find out more about the Olympus BX3 series and VS120, visit us at booth 14, or go to www.olympus-europa.com.


Please contact:


Olympus:

Ralf Schäfer (Marketing Communications Manager Microscopy)

Olympus Europa Holding GmbH,

Hamburg, GER

Tel: +49 (0) 40 23773 5913

Fax: +49 (0) 40 23773 505 913

E-mail: microscopy@olympus-europa.com

Web: www.microscopy.olympus.eu


Text:

Victoria Coupe (Account Manager)

Alto Marketing

Southampton, UK

Tel: +44 (0) 1489 557 672

Fax: +44 (0) 1489 559 246

E-mail: victoriac@alto-marketing.com

Web: www.alto-marketing.com


Olympus media contact in the USA:

Ilene Semiatin

Edge Communications Inc.

White Plains, NY 10605

Tel.: +1.914.684.0959

ilene@edge-comm.net

PromoCell GmbH

PromoKine is now adding more than 200 new ELISA kits for target molecules which play integral roles in cell signaling research.

PromoCell GmbH

PromoKine currently offers ~400 ELISA kits for detecting and quantifying the "free" forms of human, mouse, rat, monkey and pig cytokines, growth factors and other cell biology target molecules in cell culture supernatants, plasma, serum and other body fluids.  Some can even be used with tissue lysates! Our ready-to-use ELISA kits are very convenient, including a user-friendly and easy-to-follow protocol along with all the necessary components to perform a highly sensitive, reliable and reproducible ELISA.

In addition, we also provide cost-effective ELISA Development Kits containing all required reagents to assay your target protein/peptide in ten 96-well microtiter plates (approximately 1,000 assays per kit).

PromoKine is now adding more than 200 new ELISA kits for target molecules which play integral roles in cell signaling research; such as diverse interleukins, FGFs, CD markers, BMPs, MIPs, MMPs and MCPs as well as Activin A, beta-NGF, Cardiotrophin, Lymphotactin, Oncostatin M, Insulin and several other hormones. We also have launched a new line of Cell-based Phosphorylation ELISAs.

Along with this, we are extending our comprehensive product line of recombinant cytokines, growth factors, soluble receptors, hormones and other proteins/peptides involved in cell signaling as well as our wide range of antibodies against these molecules.


Test our new ELISAs and get one of our highly coveted t-shirts for free. See our current promotion at www.promokine.info/promotion


More Information: 

PromoCell GmbH

Sickingenstrasse 63/65

69126 Heidelberg
Germany

info@promokine.info
www.promokine.info

Sartorius Stedim Biotech

Sartorius Stedim Biotech develops next generation of its successful single-use laboratory bioreactor.

Sartorius Stedim Biotech
  • Proven glass bioreactor design with the efficiency and flexibility of single-use systems
  • New single-use sensors for non-invasive measurement of the pH and dissolved oxygen
  • Connection Boxes for BIOSTAT® controllers and other brands of bioreactor controller


Sartorius Stedim Biotech (SSB), a leading international equipment provider for the biopharmaceutical industry, presents UniVessel® SU, the second generation of its successful single-use bioreactor. This single-use stirred tank bioreactor can be operated in a choice of working volumes ranging from 0.6L to 2L, and is suitable for the cultivation of mammalian cells, including stem cells, insect and plant cells. Typical areas of application for the UniVessel® SU are process development and optimization, as well as production of seed cultures and cell banks.

Fast and flexible for efficient management of peak workloads despite challenging timelines UniVessel® SU combines the proven design of conventional glass vessels with the efficiency and flexibility of single-use systems. Supplied as a completely preassembled and presterilized unit, this laboratory bioreactor is instantly ready to use right out of the box. It eliminates the need for labor-intensive steps, such as autoclaving or installation of probes, minimizing the time needed for preparation. The new UniVessel® SU can be used interchangeably with glass vessels to help laboratories better manage peak workloads despite challenging timelines.

Single-use sensors for non-invasive measurement of pH and dissolved oxygen Each UniVessel® SU is equipped with integrated single-use sensors for pH and dissolved oxygen measurement. This proven single-use sensor technology, which SSB also uses in its BIOSTAT® RM and BIOSTAT® STR disposable bioreactors, measures the pH and DO values non-invasively, thus eliminating time-consuming autoclaving and risk-prone insertion of probes in the culture vessel.

Connection Boxes interface UniVessel® SU with existing bioreactor controllers UniVessel® SU is compatible with SSB BIOSTAT® controllers and can also be operated with nearly any other brand of bioreactor controller. This saves customers from having to buy expensive new equipment. The new UniVessel® SU Connection Box enables the integrated single-use sensors of UniVessel® SU to be used with existing controllers. Up to four bioreactor controllers can be interfaced per Connection Box. The sensor calibration data can be read in easily by a barcode scanner in an error-free manner.


Contact for Sartorius Stedim Biotech

Karin Kleist

Group Corporate Communications

+49.(0)551.308.3615

karin.kleist@sartorius.com

www.sartorius.com

Thermo Fisher Scientific

Thermo Fisher Scientific releases new small benchtop centrifuge, which provides scientists with outstanding capacity in a compact design.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. has launched a new small benchtop centrifuge to meet clinical and research needs alike.

“Centrifuges are in constant use and demand so preventing downtime and bottlenecks is crucial,” said Maurizio Merli, product director, Thermo Fisher Scientific. “With features designed for simplicity, safety and flexibility, the new small benchtop centrifuges can help scientists save time and maximize resources.”

The new centrifuges provide:

  • Application flexibility, convenient cleaning and ease-of-use with Thermo Scientific Auto-Lock rotor exchange
  • Versatility to spin blood tubes, conical tubes, microtubes and microplate compatibility with sealing options
  • One-handed sample protection with Thermo Scientific ClickSeal biocontainment lids, certified by the Public Health Laboratory Service in Porton Down
  • Intuitive glove and detergent-friendly interface with a bright display, one-touch operation with pre-set protocol options and optional password protection

More information:

Phone +44 870 609 9203
www.thermoscientific.com/smallbenchcentrifuge

Novozymes Biopharma

A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.

Novozymes Biopharma

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

Designed by R-Tech Ueno, RU-101 ophthalmic solution is being trialled as a therapy for severe dry eye, for which no effective treatment is currently available. The recombinant human albumin is part of Novozymes Biopharma’s albumin range. Novozymes Biopharma has a strong reputation in the industry for helping customers in the safe and successful commercialization and approval of new products.

The prevalence of severe dry eye, where patients suffer from instability of the tear film, continues to increase. It is the most diagnosed of all ophthalmic disorders and estimates put the market at approximately 1.5 billion USD. The trials for RU-101 ophthalmic solution will move ahead in two stages, the first of which will assess safety using a placebo control, and allow confirmation of the maximum dose. The second stage will then use this maximum dose for 12 weeks to evaluate the safety and effectiveness of RU-101 ophthalmic solution.

Dermot Pearson, Marketing Director at Novozymes Biopharma said, “Novozymes is dedicated to supporting our customers in the drug development and testing stages, and in assisting with the optimisation of their pathways through regulatory approval procedures. We are therefore delighted that RU-101 ophthalmic solution has been approved for clinical testing.”

Novozymes Biopharma’s recombinant albumin is designed to provide quality performance benefits when included in drugs developed by our customers. It was selected as a key component of this novel therapy back in 2011, due to its proven high quality and enhanced safety profile. Animal-free, with an exceptional purity profile and convenient liquid format at room temperature, recombinant albumin delivers consistent levels of quality, leading to reduced lot testing and vendor auditing.

All Novozymes’ recombinant human albumins deliver stable, safe and regulatory compliant ingredients for drug delivery and formulation, and are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP). 

For more information on Novozymes Biopharma’s recombinant human albumin range, please visit http://bit.ly/novozymesbiopharma


Contact:                                                          

Novozymes Biopharma:         

Sally Vernon, Marketing Communications Manager

Email: SYKE@novozymes.com

Tel. +44 115 955 3355

Sony DADC/Harvard’s Wyss Institute

the Wyss Institute for Biologically Inspired Engineering at Harvard University and Sony DADC announced a collaboration that will harness Sony DADC’s global manufacturing expertise to further advance the Institute’s Organs-on-Chips technologies.

Sony DADC/Harvard’s Wyss Institute

Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells – allowing researchers to recapitulate the physiological and mechanical functions of the organs, and to observe what happens in real time.   The goal is to provide more predictive and useful measures of the efficacy and safety of new drugs in humans – and at a fraction of the time and costs associated with traditional animal testing. 

“We are excited to apply Sony DADC’s deep manufacturing expertise to confront one of the major challenges in the life sciences by helping to accelerate the translation of the Wyss Institute’s Organ-on-Chips from the benchtop to the marketplace,” said Christoph Mauracher, Senior Vice President of the BioSciences division of Sony DADC. “The Organs-on-Chips have the potential to revolutionize testing of drugs, chemicals, toxins and cosmetics.” 

This collaboration builds on the momentum the Wyss Institute team has gained recently on its Organs-on-Chips research program.  With support from Defense Advanced Research Projects Agency (DARPA)*, National Institutes of Health (NIH), Food and Drug Administration (FDA), and pharmaceutical partners, more than ten Organs-on-Chips are currently under development at the Wyss Institute, including a lung, heart, liver, kidney, bone marrow, and gut-on-a-chip; there is also a major effort to integrate these organ chips into “human body on-chips” that mimic whole body physiology.  

In February, Wyss Founding Director Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research for the lung-on-a-chip.  This month, the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his “seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity.”

“Our work with Sony DADC is a wonderful example of the Wyss Institute model in action,” said Ingber.  “We collaborate with industry to help de-risk the technologies we develop, both technically and commercially, and therefore expedite their translation into real world applications.”  

*Part of this research was sponsored by the U.S. Army Research Office (ARO) and DARPA; the views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of ARO, DARPA or the U.S. Government.


Contacts:

Wyss Institute for Biologically Inspired Engineering 

Kristen M. Kusek

+1 617-432-8266

Kristen.kusek@wyss.harvard.edu

http://wyss.harvard.edu


Sony DADC

Manfred Koranda

+43 6246 880 8143

manfred.koranda@sonydadc.com

biosciences.sonydadc.com

Beckman Coulter

The PA 800 plus next-generation CE-platform from Beckman Coulter Life Sciences provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure.

Beckman Coulter

Beckman Coulter Life Sciences have products offering a range of biotech, analytical chemistry and industrial applications at the Pittcon Conference and Expo, March 18-21, in Philadelphia, USA.

One example of new applications is found with the PA 800 plus next-generation capillary electrophoresis (CE) platform, which provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure. Originally designed with biopharmaceutical analysis in mind, the system can also be used in food and beverage quality studies for monosaccharide and protein analysis, and in the quantitative characterization of ions, organic acids and other charged or polar molecules of importance.


Beckman Coulter, Inc., based in California, USA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.


Contacts:

Hillary Hunter, Beckman Coulter Life Sciences Public Relations

hillarythunter@beckman.com

Tel: +1 714 961 5620

Jennie Wilde, Carver Wilde Communications

jennie@carverwilde.com

Tel:  +44 (0)20 3178 5564/ +44 (0) 7799412230

Vorherige Seite4/8Nächste Seite

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/service/products/pos/4.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper